Anti-CD20 mediated B cell depletion exerts a distinct influence on T cell immunity by decreasing effector memory CD4 Th17 and Th1.17 subsets in multiple sclerosis
Immunobiology, 2026
Evertsson B., Ruffin N., Theorell J., Huang J., Högelin K., Khademi M., Piehl F., Al Nimer F.
| Disease area | Application area | Sample type | Products |
|---|---|---|---|
Neurology | Pathophysiology | Plasma | Olink Target 96 |
Abstract
Multiple sclerosis (MS) is driven by dysregulated B and T cell interactions. Anti-CD20 B cell depletion with rituximab (RTX) strongly suppresses MS disease activity, yet how it relates to T cell immunity is unclear. We analysed clinically acquired flow cytometry data from 310 people with MS before and six months after RTX initiation, with plasma proteomics and CD4 T cell receptor sequencing in subgroups. Baseline T cell profiles correlated with B cell numbers, age, and HLA-DRB1*15:01 status. To limit confounding from prior therapies, RTX-associated changes were primarily assessed in treatment-naïve participants, in whom effector memory Th17 and Th1.17 CD4 subsets were selectively reduced, while CD8 subsets, the plasma inflammatory proteome, and CD4 clonality were largely unchanged. This observational study cannot establish causality, but identifies distinct memory CD4 subsets, relevant to MS disease activity, that are measurable in routine clinical flow cytometry.